Abera and partners from The Netherlands, Germany, Switzerland, Denmark and Italy receive more than 2.5 MEUR of funding from the EU for the project Novel vaccine vectors resist pathogen challenge – VacPath. VacPath is a Horizon 2020 MSCA-funded Innovative Training Network that aims to develop novel vector-based vaccines eliciting mucosal immunity against the intracellular bacterium Chlamydia trachomatis.
For more detailed descriptions of the project, please click below:
https://cordis.europa.eu/project/rcn/217946/factsheet/en
https://euraxess.ec.europa.eu/jobs/365033
